Search Videos and More
News
Dana-Farber Research News 04.01.2025
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from March 1 through March 15.
News
Potential Targeted Therapy for Pediatric Brain Cancer Identified by Dana-Farber/Boston Children's Team
An international team of clinical collaborators, led by physician scientists from Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, performed a first-ever clinical test of the targeted therapy avapritinib in pediatric and young patients with a form of high-grade glioma.
News
AI Learns Genomic “Language” to Advance Cancer Treatment
The human genome is a sequence of Ts, Gs, Cs, and As that is about 3 billion letters long. And, says Bradley Bernstein, MD, PhD, chair of Dana-Farber’s Department of Cancer Biology, “there’s no dictionary or guide for reading it.”
News
Treatment of Recurrent Endometrial Cancer with Metformin, Letrozole, and Abemaciclib is Safe and Promising, Dana-Farber Research Shows
A combination, triplet therapy that targets cancer cells from within and without caused tumors to shrink or stabilize in nearly all patients with recurrent or persistent estrogen receptor- (ER-) positive endometrial cancer, results from a recent phase 2 clinical trial show.
News
Dana-Farber Research News 03.15.2025
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from February 16 through February 28.
News
Novel Approaches in Waldenström's Macroglobulinemia
Dana-Farber Cancer Institute researchers will present important research studies during the 2025 ASCO Genitourinary (GU) Cancers Symposium, on February 13-15, 2025, in San Francisco, Calif.
News
Novel Stem Cell Therapy Safely Repairs Irreversible Corneal Damage in Clinical Trial
An expanded phase clinical trial that tested a groundbreaking, experimental stem cell treatment for blinding cornea injuries found the treatment was feasible and safe in 14 patients who were treated and followed for 18 months, and there was a high proportion of complete or partial success.
Video
Kidney Cancer Conference Highlights from ASCO GU 2025
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates, focused on clear cell renal cell carcinoma (ccRCC), you need to know from GU ASCO 2025.
Video
Bladder Cancer Conference Highlights from ASCO GU 2025
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the bladder cancer clinical updates you need to know from GU ASCO 2025. Highlights in this video include more details on the CheckMate274, NIAGRA, and INDUCT trials.
Video
Prostate Cancer Conference Highlights from ASCO GU 2025
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates you need to know from GU ASCO 2025. This video highlights updates in mCRPC and oligometastatic prostate cancer trials.
News
Dana-Farber Research News 03.01.2025
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from February 1 through February 15.
Video
Wenxin (Vincent) Xu, MD presents a potential biomarker (KIM-1)
Evaluation of circulating kidney injury marker-1 (KIM-1) as a prognostic and predictive biomarker in advanced renal cell carcinoma (aRCC): Post-hoc analysis of CheckMate 214.